{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T06:40:22Z","timestamp":1792478422595,"version":"4.5.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"DOI":"10.1007\/s11912-026-01844-w","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T05:43:57Z","timestamp":1792475037000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antibody\u2013Drug Conjugates in Biliary Tract Cancer: Current Evidence, Emerging Targets, and Future Directions"],"prefix":"10.1007","volume":"28","author":[{"given":"Hu","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7575-4322","authenticated-orcid":false,"given":"Hui","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,20]]},"reference":[{"issue":"9","key":"1844_CR1","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"JM Banales","year":"2020","unstructured":"Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17(9):557\u201388.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"1844_CR2","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jhep.2019.03.013","volume":"71","author":"P Bertuccio","year":"2019","unstructured":"Bertuccio P, Malvezzi M, Carioli G, et al. Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. J Hepatol. 2019;71(1):104\u201314.","journal-title":"J Hepatol"},{"issue":"3","key":"1844_CR3","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"Suppl 1","key":"1844_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/liv.14095","volume":"39","author":"SA Khan","year":"2019","unstructured":"Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma: epidemiology and risk factors. Liver Int. 2019;39(Suppl 1):19\u201331.","journal-title":"Liver Int"},{"issue":"9","key":"1844_CR5","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1158\/2159-8290.CD-17-0245","volume":"7","author":"JW Valle","year":"2017","unstructured":"Valle JW, Lamarca A, Goyal L, et al. New horizons for precision medicine in biliary tract cancers. Cancer Discov. 2017;7(9):943\u201362.","journal-title":"Cancer Discov"},{"issue":"14","key":"1844_CR6","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273\u201381.","journal-title":"N Engl J Med"},{"issue":"8","key":"1844_CR7","doi-asserted-by":"publisher","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"DY Oh","year":"2022","unstructured":"Oh DY, Ruth He A, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 2022;1(8):EVIDoa2200015.","journal-title":"NEJM Evid"},{"issue":"10391","key":"1844_CR8","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401(10391):1853\u201365.","journal-title":"Lancet"},{"issue":"5","key":"1844_CR9","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","volume":"22","author":"A Lamarca","year":"2021","unstructured":"Lamarca A, Palmer DH, Wasan HS, et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, multicentre study. Lancet Oncol. 2021;22(5):690\u2013701.","journal-title":"Lancet Oncol"},{"issue":"17","key":"1844_CR10","doi-asserted-by":"publisher","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-18-0078","volume":"24","author":"MA Lowery","year":"2018","unstructured":"Lowery MA, Ptashkin R, Jordan E, et al. Comprehensive molecular profiling of intra- and extrahepatic cholangiocarcinomas: potential targets for intervention. Clin Cancer Res. 2018;24(17):4154\u201361.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1844_CR11","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21(5):671\u201384.","journal-title":"Lancet Oncol"},{"issue":"6","key":"1844_CR12","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Macarulla T, Javle MM, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(6):796\u2013807.","journal-title":"Lancet Oncol"},{"issue":"11","key":"1844_CR13","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","volume":"7","author":"AX Zhu","year":"2021","unstructured":"Zhu AX, Macarulla T, Javle MM, et al. Final overall survival and results from the randomized, placebo-controlled phase III study of ivosidenib in patients with advanced cholangiocarcinoma with IDH1 mutation (ClarIDHy). JAMA Oncol. 2021;7(11):1669\u201377.","journal-title":"JAMA Oncol"},{"key":"1844_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.humpath.2020.08.006","volume":"105","author":"N Hiraoka","year":"2020","unstructured":"Hiraoka N, Nitta H, Ohba A, et al. Details of human epidermal growth factor receptor 2 status in 454 cases of biliary tract cancer. Hum Pathol. 2020;105:9\u201319.","journal-title":"Hum Pathol"},{"issue":"8","key":"1844_CR15","doi-asserted-by":"publisher","first-page":"e1051","DOI":"10.1093\/oncolo\/oyae076","volume":"29","author":"Y Kim","year":"2024","unstructured":"Kim Y, Jee S, Kim H, et al. HER2, and MET gene amplification and protein expression profiles in biliary tract cancer and their prognostic significance. Oncologist. 2024;29(8):e1051\u201360.","journal-title":"Oncologist"},{"issue":"5","key":"1844_CR16","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrd.2016.268","volume":"16","author":"A Beck","year":"2017","unstructured":"Beck A, Goetsch L, Dumontet C, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16(5):315\u201337.","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"1844_CR17","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1111\/cas.12966","volume":"107","author":"Y Ogitani","year":"2016","unstructured":"Ogitani Y, Hagihara K, Oitate M, et al. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016;107(7):1039\u201346.","journal-title":"Cancer Sci"},{"key":"1844_CR18","unstructured":"Food US, Administration D. FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumors [Internet]. Silver Spring (MD): FDA; 2024 Apr 5 [cited 2026 Jul 17]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2"},{"issue":"16","key":"1844_CR19","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384(16):1529\u201341.","journal-title":"N Engl J Med"},{"issue":"22","key":"1844_CR20","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1200\/JCO.20.03489","volume":"39","author":"ST Tagawa","year":"2021","unstructured":"Tagawa ST, Balar AV, Petrylak DP, et al. TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. J Clin Oncol. 2021;39(22):2474\u201385.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1844_CR21","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","volume":"384","author":"T Powles","year":"2021","unstructured":"Powles T, Rosenberg JE, Sonpavde GP, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med. 2021;384(12):1125\u201335.","journal-title":"N Engl J Med"},{"issue":"1","key":"1844_CR22","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s11523-025-01193-x","volume":"21","author":"Y Shin","year":"2026","unstructured":"Shin Y, Shin J, Jeong H, et al. Claudin-18.2 and Trop-2 as emerging biomarkers in biliary tract cancers: expression analysis and therapeutic potential. Target Oncol. 2026;21(1):127\u201337.","journal-title":"Target Oncol"},{"issue":"14","key":"1844_CR23","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1158\/0008-5472.CAN-23-0510","volume":"83","author":"Y Bei","year":"2023","unstructured":"Bei Y, He J, Dong X, et al. Targeting CD44 variant 5 with an antibody\u2013drug conjugate is an effective therapeutic strategy for intrahepatic cholangiocarcinoma. Cancer Res. 2023;83(14):2405\u201320.","journal-title":"Cancer Res"},{"issue":"1","key":"1844_CR24","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","volume":"42","author":"F Meric-Bernstam","year":"2024","unstructured":"Meric-Bernstam F, Makker V, Oaknin A, et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol. 2024;42(1):47\u201358.","journal-title":"J Clin Oncol"},{"key":"1844_CR25","doi-asserted-by":"crossref","unstructured":"Neureiter D, Bekric D, Mayr C et al. Emerging claudin-18.2 antagonists in the treatment of biliary tract cancer. Expert Opin Emerg Drugs 2026:1\u201311.","DOI":"10.1080\/14728214.2026.2681745"},{"issue":"1","key":"1844_CR26","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jhep.2025.08.018","volume":"84","author":"SL Chan","year":"2026","unstructured":"Chan SL, Lamarca A, Hsu C, et al. New targets and new drugs for hepatobiliary cancers. J Hepatol. 2026;84(1):213\u201328.","journal-title":"J Hepatol"},{"issue":"8","key":"1844_CR27","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1001\/jamaoncol.2025.1791","volume":"11","author":"D Bryant","year":"2025","unstructured":"Bryant D, Feldman R, Abdulla F, et al. A real-world experience in pan-tumor testing for HER2 IHC in more than 65,000 solid tumors. JAMA Oncol. 2025;11(8):919\u201321.","journal-title":"JAMA Oncol"},{"issue":"4","key":"1844_CR28","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.livres.2024.11.005","volume":"8","author":"A Ainiwaer","year":"2024","unstructured":"Ainiwaer A, Cheng J, Lang R, et al. Chinese expert consensus on the clinical application of molecular diagnostics in hepatobiliary cancers (2024 edition). Liver Res. 2024;8(4):195\u2013206.","journal-title":"Liver Res"},{"issue":"27","key":"1844_CR29","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1200\/JCO.23.02010","volume":"42","author":"A Ohba","year":"2024","unstructured":"Ohba A, Morizane C, Kawamoto Y, et al. Trastuzumab deruxtecan in human epidermal growth factor receptor 2-expressing biliary tract cancer (HERB; NCCH1805): a multicenter, single-arm, phase II trial. J Clin Oncol. 2024;42(27):3207\u201317.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1844_CR30","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387(1):9\u201320.","journal-title":"N Engl J Med"},{"issue":"12","key":"1844_CR31","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/S1470-2045(22)00621-0","volume":"23","author":"F Meric-Bernstam","year":"2022","unstructured":"Meric-Bernstam F, Beeram M, Hamilton E, et al. Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study. Lancet Oncol. 2022;23(12):1558\u201370.","journal-title":"Lancet Oncol"},{"issue":"7","key":"1844_CR32","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/S1470-2045(23)00242-5","volume":"24","author":"JJ Harding","year":"2023","unstructured":"Harding JJ, Fan J, Oh DY, et al. Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study. Lancet Oncol. 2023;24(7):772\u201382.","journal-title":"Lancet Oncol"},{"issue":"Suppl 16","key":"1844_CR33","first-page":"4009","volume":"42","author":"JJ Harding","year":"2024","unstructured":"Harding JJ, Fan J, Oh DY, et al. Updated overall survival and subgroup analyses from HERIZON-BTC-01: zanidatamab in HER2-amplified biliary tract cancer [conference abstract]. J Clin Oncol. 2024;42(Suppl 16):4009. [Abstract; full-text publication pending].","journal-title":"J Clin Oncol"},{"key":"1844_CR34","unstructured":"Food US, Administration D. FDA grants accelerated approval to zanidatamab-hrii for previously treated unresectable or metastatic HER2-positive biliary tract cancer [Internet]. Silver Spring (MD): FDA; 2024 Nov 20 [cited 2026 Jul 17]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-zanidatamab-hrii-previously-treated-unresectable-or-metastatic-her2"},{"issue":"9","key":"1844_CR35","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1080\/14712598.2025.2556903","volume":"25","author":"J Yoon","year":"2025","unstructured":"Yoon J, Oh DY. An evaluation of zanidatamab, a novel, anti-HER2 biparatopic antibody, for the treatment of biliary tract cancer. Expert Opin Biol Ther. 2025;25(9):935\u201346.","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"1844_CR36","doi-asserted-by":"publisher","first-page":"101635","DOI":"10.1016\/j.jhepr.2025.101635","volume":"8","author":"S Welland","year":"2026","unstructured":"Welland S, Z\u00f6ller AK, Mavroeidi IA, et al. Clinical practice and implications of biomarker testing in biliary tract cancer: an observational study. JHEP Rep. 2026;8(1):101635.","journal-title":"JHEP Rep"},{"issue":"11","key":"1844_CR37","doi-asserted-by":"publisher","first-page":"12071","DOI":"10.1002\/cam4.5893","volume":"12","author":"EGE de Vries","year":"2023","unstructured":"de Vries EGE, R\u00fcschoff J, Lolkema M, et al. Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer\/cholangiocarcinoma. Cancer Med. 2023;12(11):12071\u201383.","journal-title":"Cancer Med"},{"issue":"26","key":"1844_CR38","first-page":"00187","volume":"S0923\u20137534","author":"DY Ruan","year":"2026","unstructured":"Ruan DY, Lin SY, Huang JJ, et al. Preclinical characterization and phase I results of TQB2102, a first-in-class HER2 biparatopic antibody-drug conjugate, in patients with advanced solid tumors. Ann Oncol. 2026;S0923\u20137534(26):00187\u20130. [Epub ahead of print].","journal-title":"Ann Oncol"},{"issue":"16suppl","key":"1844_CR39","first-page":"4572","volume":"41","author":"X Sheng","year":"2023","unstructured":"Sheng X, Yan X, Wang J, et al. Pooled analysis of two pivotal studies of disitamab vedotin (RC48) in HER2-positive locally advanced\/metastatic urothelial carcinoma. J Clin Oncol. 2023;41(16suppl):4572.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1844_CR40","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/cac2.12577","volume":"44","author":"J Wang","year":"2024","unstructured":"Wang J, Liu Y, Zhang Q, et al. Disitamab vedotin, a HER2-directed antibody-drug conjugate, in patients with HER2-overexpression and HER2-low advanced breast cancer: a phase I\/Ib study. Cancer Commun (Lond). 2024;44(7):833\u201351.","journal-title":"Cancer Commun (Lond)"},{"issue":"1","key":"1844_CR41","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1080\/10717544.2022.2069883","volume":"29","author":"F Shi","year":"2022","unstructured":"Shi F, Liu Y, Zhou X, et al. Disitamab vedotin: a novel antibody-drug conjugate for cancer therapy. Drug Deliv. 2022;29(1):1335\u201344.","journal-title":"Drug Deliv"},{"issue":"7","key":"1844_CR42","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S1470-2045(24)00159-1","volume":"25","author":"Y Ma","year":"2024","unstructured":"Ma Y, Huang Y, Zhao Y, et al. BL-B01D1, a first-in-class EGFR\u2013HER3 bispecific antibody\u2013drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study. Lancet Oncol. 2024;25(7):901\u201311.","journal-title":"Lancet Oncol"},{"issue":"10","key":"1844_CR43","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1038\/s41591-025-03792-7","volume":"31","author":"C Liu","year":"2025","unstructured":"Liu C, Liu D, Ji Y, et al. A bispecific antibody\u2013drug conjugate targeting EGFR and HER3 in metastatic esophageal squamous cell carcinoma: a phase 1b trial. Nat Med. 2025;31(10):3485\u201391.","journal-title":"Nat Med"},{"issue":"36","key":"1844_CR44","doi-asserted-by":"publisher","first-page":"4511","DOI":"10.3748\/wjg.15.4511","volume":"15","author":"J Harder","year":"2009","unstructured":"Harder J, Waiz O, Otto F, et al. EGFR and HER2 expression in advanced biliary tract cancer. World J Gastroenterol. 2009;15(36):4511\u20137.","journal-title":"World J Gastroenterol"},{"issue":"3","key":"1844_CR45","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/path.1779","volume":"206","author":"K Nakazawa","year":"2005","unstructured":"Nakazawa K, Dobashi Y, Suzuki S, et al. Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers. J Pathol. 2005;206(3):356\u201365.","journal-title":"J Pathol"},{"issue":"Supplement","key":"1844_CR46","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.4103\/0973-1482.206864","volume":"14","author":"W Zhou","year":"2018","unstructured":"Zhou W, Jiang C, Zhan N, et al. Human epidermal growth factor receptor 2, epidermal growth factor receptor, and c-MET overexpression and survival in biliary tract cancer: a meta-analysis. J Cancer Res Ther. 2018;14(Supplement):S28\u201335.","journal-title":"J Cancer Res Ther"},{"issue":"10","key":"1844_CR47","doi-asserted-by":"publisher","first-page":"e0206007","DOI":"10.1371\/journal.pone.0206007","volume":"13","author":"A Lamarca","year":"2018","unstructured":"Lamarca A, Galdy S, Barriuso J, et al. The HER3 pathway as a potential target for inhibition in patients with biliary tract cancers. PLoS ONE. 2018;13(10):e0206007.","journal-title":"PLoS ONE"},{"issue":"32","key":"1844_CR48","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1200\/JCO-25-00109","volume":"43","author":"X Bian","year":"2025","unstructured":"Bian X, Yang T, Yin H, et al. Efficacy and safety of BL-B01D1 in patients with locally advanced or metastatic urothelial carcinoma: a phase II clinical trial. J Clin Oncol. 2025;43(32):3505\u201315.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1844_CR49","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.annonc.2026.01.009","volume":"37","author":"SD Hong","year":"2026","unstructured":"Hong SD, Wang YS, Zhao HY, et al. Izalontamab brengitecan (iza-bren; BL-B01D1), a first-in-class EGFR\u2013HER3 bispecific antibody\u2013drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials. Ann Oncol. 2026;37(6):813\u201324.","journal-title":"Ann Oncol"},{"issue":"10516","key":"1844_CR50","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1016\/S0140-6736(25)01954-3","volume":"406","author":"Y Yang","year":"2025","unstructured":"Yang Y, Zhou H, Tang L, et al. Izalontamab brengitecan, an EGFR and HER3 bispecific antibody\u2013drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China. Lancet. 2025;406(10516):2235\u201343.","journal-title":"Lancet"},{"issue":"Suppl 2","key":"1844_CR51","doi-asserted-by":"publisher","first-page":"S233","DOI":"10.1016\/j.annonc.2024.08.063","volume":"35","author":"Z Lu","year":"2024","unstructured":"Lu Z, Chang L, Zhou J, et al. BL-B01D1, an EGFR\u00d7HER3 bispecific antibody\u2013drug conjugate (ADC), in patients with locally advanced or metastatic biliary tract carcinoma (BTC) [conference abstract]. Ann Oncol. 2024;35(Suppl 2):S233. Abstract 54P. [Abstract; full-text publication pending].","journal-title":"Ann Oncol"},{"issue":"12","key":"1844_CR52","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1016\/j.ccell.2025.09.012","volume":"43","author":"J Zhong","year":"2025","unstructured":"Zhong J, Wu L, Song Z, et al. TROP-2-targeted antibody\u2013drug conjugate SHR-A1921 for advanced or metastatic solid tumors: a first-in-human phase 1 study. Cancer Cell. 2025;43(12):2268\u2013e22813.","journal-title":"Cancer Cell"},{"issue":"12","key":"1844_CR53","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1136\/jcp-2023-209268","volume":"78","author":"P Yan","year":"2025","unstructured":"Yan P, Dong Y, Zhang F, et al. Claudin18.2 expression and its clinicopathological feature in adenocarcinoma from various parts. J Clin Pathol. 2025;78(12):815\u201321.","journal-title":"J Clin Pathol"},{"issue":"9","key":"1844_CR54","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1038\/s41591-025-03783-8","volume":"31","author":"J Liu","year":"2025","unstructured":"Liu J, Yang J, Sun Y, et al. CLDN18.2-targeting antibody\u2013drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial. Nat Med. 2025;31(9):3028\u201336.","journal-title":"Nat Med"},{"key":"1844_CR55","doi-asserted-by":"publisher","first-page":"115808","DOI":"10.1016\/j.ejca.2025.115808","volume":"230","author":"C Bai","year":"2025","unstructured":"Bai C, Zheng Y, Sun M, et al. Tecotabart vedotin in Claudin 18.2-positive advanced gastric\/gastroesophageal junction cancer: a Bayesian phase 1\/2 clinical trial. Eur J Cancer. 2025;230:115808.","journal-title":"Eur J Cancer"},{"key":"1844_CR56","doi-asserted-by":"publisher","first-page":"175883592312179","DOI":"10.1177\/17588359231217967","volume":"16","author":"Y Kubota","year":"2024","unstructured":"Kubota Y, Shitara K. Zolbetuximab for Claudin18.2-positive gastric or gastroesophageal junction cancer. Ther Adv Med Oncol. 2024;16:17588359231217967.","journal-title":"Ther Adv Med Oncol"},{"issue":"23","key":"1844_CR57","doi-asserted-by":"publisher","first-page":"3764","DOI":"10.3390\/cancers17233764","volume":"17","author":"A Dominguez Wiscovitch","year":"2025","unstructured":"Dominguez Wiscovitch A, Sanchez Mendez RJ, Chuy J. CLDN18.2-targeted therapy in gastrointestinal cancers. Cancers (Basel). 2025;17(23):3764.","journal-title":"Cancers (Basel)"},{"issue":"Suppl","key":"1844_CR58","doi-asserted-by":"publisher","first-page":"3030","DOI":"10.1200\/JCO.2026.44.16_suppl.3030","volume":"44","author":"S Cheng","year":"2026","unstructured":"Cheng S, Shen L, et al. Phase I study of BL-M05D1, a novel CLDN18.2-directed antibody\u2013drug conjugate (ADC), in patients with locally advanced or metastatic CLDN18.2-expressing solid tumors [conference abstract]. J Clin Oncol. 2026;44(Suppl):3030. Abstract 3030. [Abstract; full-text publication pending].","journal-title":"J Clin Oncol"},{"issue":"6","key":"1844_CR59","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1038\/s41591-025-03600-2","volume":"31","author":"Y Ma","year":"2025","unstructured":"Ma Y, Yang Y, Huang Y, et al. A B7H3-targeting antibody\u2013drug conjugate in advanced solid tumors: a phase 1\/1b trial. Nat Med. 2025;31(6):1949\u201357.","journal-title":"Nat Med"},{"key":"1844_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.615691","volume":"11","author":"EE Geerdes","year":"2021","unstructured":"Geerdes EE, Sideras K, Aziz MH, et al. Cancer cell B7-H3 expression is more prevalent in the pancreato-biliary subtype of ampullary cancer than in pancreatic cancer. Front Oncol. 2021;11:615691.","journal-title":"Front Oncol"},{"issue":"1","key":"1844_CR61","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2026.2614669","volume":"18","author":"S Crescioli","year":"2026","unstructured":"Crescioli S, Kaplon H, Chenoweth A, et al. Antibodies to watch in 2026. mAbs. 2026;18(1):2614669.","journal-title":"mAbs"},{"issue":"4","key":"1844_CR62","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S1470-2045(25)00733-8","volume":"27","author":"ML Johnson","year":"2026","unstructured":"Johnson ML, Patel MR, Falchook GS, et al. Ifinatamab deruxtecan, a B7-H3-directed antibody\u2013drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1\/2 trial. Lancet Oncol. 2026;27(4):491\u2013501.","journal-title":"Lancet Oncol"},{"issue":"4","key":"1844_CR63","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.ccell.2026.02.006","volume":"44","author":"J Duan","year":"2026","unstructured":"Duan J, Sun Y, Wang Q, et al. HS-20093, a B7-H3-targeted antibody\u2013drug conjugate in lung cancer: results from the ARTEMIS-001 phase 1a\/b trial. Cancer Cell. 2026;44(4):846\u2013e8573.","journal-title":"Cancer Cell"},{"issue":"852","key":"1844_CR64","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adp2595","volume":"18","author":"Z Nehme","year":"2026","unstructured":"Nehme Z, Muller M, Brochon J, et al. Claudin-1 targeting suppresses tumor growth, invasion, and metastasis in patient-derived cholangiocarcinoma models. Sci Transl Med. 2026;18(852):eadp2595.","journal-title":"Sci Transl Med"},{"issue":"3","key":"1844_CR65","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1159\/000545308","volume":"104","author":"S Camera","year":"2026","unstructured":"Camera S, Rimini M, Foti S, et al. Anti-human epidermal growth factor receptor-2 therapies in biliary tract cancers: a meta-analysis on disease location, human epidermal growth factor receptor-2 status, and survival outcomes. Oncology. 2026;104(3):306\u201318.","journal-title":"Oncology"},{"issue":"12","key":"1844_CR66","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1038\/s41591-024-03389-6","volume":"30","author":"K O\u2019Leary","year":"2024","unstructured":"O\u2019Leary K. First tumor-agnostic approval for an ADC. Nat Med. 2024;30(12):3392.","journal-title":"Nat Med"},{"issue":"1","key":"1844_CR67","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jhep.2025.01.007","volume":"83","author":"T Chung","year":"2025","unstructured":"Chung T, Oh S, Won J, et al. Genomic and transcriptomic signatures of sequential carcinogenesis from papillary neoplasm to biliary tract cancer. J Hepatol. 2025;83(1):119\u201330.","journal-title":"J Hepatol"},{"issue":"Suppl","key":"1844_CR68","doi-asserted-by":"publisher","first-page":"3026","DOI":"10.1200\/JCO.2026.44.16_suppl.3026","volume":"44","author":"Y Zhang","year":"2026","unstructured":"Zhang Y, Wang J, Li Y, et al. Trastuzumab deruxtecan (T-DXd) for pretreated patients in China with HER2 IHC 3\u2009+\u2009solid tumors: DESTINY-PanTumor03 Part 1 primary analysis [conference abstract]. J Clin Oncol. 2026;44(Suppl):3026. Abstract 3026. [Abstract; full-text publication pending].","journal-title":"J Clin Oncol"},{"issue":"20","key":"1844_CR69","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1080\/14796694.2025.2535171","volume":"21","author":"G Bianchini","year":"2025","unstructured":"Bianchini G, Fabi A, Guarneri V, et al. Management of trastuzumab deruxtecan-related adverse events in breast cancer: Italian expert panel recommendations. Future Oncol. 2025;21(20):2565\u201373.","journal-title":"Future Oncol"},{"issue":"Suppl 4","key":"1844_CR70","first-page":"522","volume":"40","author":"H Chae","year":"2022","unstructured":"Chae H, Curtis C, Sundaram R, et al. Liquid biopsy for diagnosis in patients with suspected pancreatic and biliary tract cancers: PREVAIL ctDNA pilot trial [conference abstract]. J Clin Oncol. 2022;40(Suppl 4):522. Abstract 522. [Abstract; full-text publication pending].","journal-title":"J Clin Oncol"},{"issue":"1","key":"1844_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.labinv.2025.104259","volume":"106","author":"H Kim","year":"2026","unstructured":"Kim H, Heo J, Cho SI, et al. Pathologist-artificial intelligence concordance in HER2 interpretation for advanced biliary tract cancer: intraobserver, interobserver, and human-artificial intelligence variability. Lab Invest. 2026;106(1):104259.","journal-title":"Lab Invest"},{"issue":"2","key":"1844_CR72","doi-asserted-by":"publisher","DOI":"10.1002\/cai2.70060","volume":"5","author":"Z Wang","year":"2026","unstructured":"Wang Z, Chen L, Rao W, Cao B, Cai M, Fan X, et al. Consensus on human epidermal growth factor receptor 2 overexpression testing in pan-tumor. Cancer Innov. 2026;5(2):e70060.","journal-title":"Cancer Innov"},{"issue":"6","key":"1844_CR73","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/s41571-025-01016-y","volume":"22","author":"CJ Robbins","year":"2025","unstructured":"Robbins CJ, Bates KM, Rimm DL. HER2 testing: evolution and update for a companion diagnostic assay. Nat Rev Clin Oncol. 2025;22(6):408\u201323.","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"1844_CR74","doi-asserted-by":"publisher","first-page":"108344","DOI":"10.1016\/j.esmoop.2026.108344","volume":"11","author":"D-Y Oh","year":"2026","unstructured":"Oh D-Y, \u0141ugowska I, Stroyakovskiy D, et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing biliary tract or pancreatic tumors: a subgroup analysis of DESTINY-PanTumor02. ESMO Open. 2026;11(8):108344.","journal-title":"ESMO Open"},{"issue":"1","key":"1844_CR75","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s10238-025-01655-6","volume":"25","author":"Y Lv","year":"2025","unstructured":"Lv Y, Cui X, Li T, et al. Mechanism of action and future perspectives of ADCs in combination with immune checkpoint inhibitors for solid tumors. Clin Exp Med. 2025;25(1):139.","journal-title":"Clin Exp Med"},{"issue":"24","key":"1844_CR76","doi-asserted-by":"publisher","first-page":"5548","DOI":"10.1158\/1078-0432.CCR-24-1513","volume":"30","author":"E Hamilton","year":"2024","unstructured":"Hamilton E, Galsky MD, Ochsenreither S, et al. Trastuzumab deruxtecan with nivolumab in HER2-expressing metastatic breast or urothelial cancer: analysis of the phase Ib DS8201-A-U105 study. Clin Cancer Res. 2024;30(24):5548\u201358.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1844_CR77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-023-01509-2","volume":"17","author":"Q Wei","year":"2024","unstructured":"Wei Q, Li P, Yang T, et al. The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors. J Hematol Oncol. 2024;17(1):1.","journal-title":"J Hematol Oncol"},{"issue":"7","key":"1844_CR78","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1038\/s41591-024-02992-x","volume":"30","author":"K Shitara","year":"2024","unstructured":"Shitara K, Bang YJ, Iwasa S, et al. Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial. Nat Med. 2024;30(7):1933\u201342.","journal-title":"Nat Med"},{"issue":"22","key":"1844_CR79","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","volume":"391","author":"A Bardia","year":"2024","unstructured":"Bardia A, Hu X, Dent R, et al. Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer. N Engl J Med. 2024;391(22):2110\u201322.","journal-title":"N Engl J Med"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01844-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-026-01844-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01844-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T06:02:13Z","timestamp":1792476133000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-026-01844-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,20]]},"references-count":79,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1844"],"URL":"https:\/\/doi.org\/10.1007\/s11912-026-01844-w","relation":{},"ISSN":["1534-6269"],"issn-type":[{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,20]]},"assertion":[{"value":"5 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"105"}}